The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial
Open accessAbstract
Importance: Patients with cerebral venous thrombosis (CVT) are at risk of recurrent venous thrombotic events (VTEs). Non-vitamin K oral anticoagulants have not been evaluated in randomized controlled trials in CVT. Objective: To compare the efficacy and safety of dabigatran etexilate with those of dose-adjusted warfarin in preventing recurrent VTEs in patients who have experienced a CVT. Design, Setting, and Participants: RE-SPECT CVT is an exploratory, prospective, randomized (1:1), parallel-group, open-label, multicenter clinical trial with blinded end-point adjudication (PROBE design). It was performed from December 21, 2016, to June 22, 2018, with a follow-up of 25 weeks, at 51 tertiary sites in 9 countries (France, Germany, India, Italy, the Netherlands, Poland, Portugal, Russia, and Spain). Adult consecutive patients with acute CVT, who were stable after 5 to 15 days of treatment with parenteral heparin, were screened for eligibility. Patients with CVT associated with central nervous system infection or major trauma were excluded, but those with intracranial hemorrhage from index CVT were allowed to participate. After exclusions, 120 patients were randomized. Data were analyzed following the intention-to-treat approach. Interventions: Dabigatran, 150 mg twice daily, or dose-adjusted warfarin for a treatment period of 24 weeks. Main Outcomes and Measures: Primary outcome was a composite of patients with a new VTE (recurrent CVT, deep vein thrombosis of any limb, pulmonary embolism, and splanchnic vein thrombosis) or major bleeding during the study period. Secondary outcomes were cerebral venous recanalization and clinically relevant non-major bleeding events. Results: In total, 120 patients with CVT were randomized to the 2 treatment groups (60 to dabigatran and 60 to dose-adjusted warfarin). Of the randomized patients, the mean (SD) age was 45.2 (13.8) years, and 66 (55.0%) were women. The mean (SD) duration of exposure was 22.3 (6.16) weeks for the dabigatran group and 23.0 (5.20) weeks for the warfarin group. No recurrent VTEs were observed. One (1.7%; 95% CI, 0.0-8.9) major bleeding event (intestinal) was recorded in the dabigatran group, and 2 (3.3%; 95% CI, 0.4-11.5) (intracranial) in the warfarin group. One additional patient (1.7; 95% CI, 0.0-8.9) in the warfarin group experienced a clinically relevant non-major bleeding event. Recanalization occurred in 33 patients in the dabigatran group (60.0%; 95% CI, 45.9-73.0) and in 35 patients in the warfarin group (67.3%; 95% CI, 52.9-79.7). Conclusions and Relevance: This trial found that patients who had CVT anticoagulated with either dabigatran or warfarin had low risk of recurrent VTEs, and the risk of bleeding was similar with both medications, suggesting that both dabigatran and warfarin may be safe and effective for preventing recurrent VTEs in patients with CVT. Trial Registration: ClinicalTrials.gov identifier: NCT02913326.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis
Rankin, J. (1957) · Scottish Medical Journal · doi:10.1177/003693305700200504 · Cited by 2,506
Ferro, J. M., Canhão, P., Stam, J., Bousser, M.-G., & Barinagarrementeria, F. (2004) · Stroke · doi:10.1161/01.str.0000117571.76197.26 · Cited by 2,315
Self-citationSaposnik, G., Barinagarrementeria, F., Brown, R. D., Bushnell, C. D., Cucchiara, B., Cushman, M., deVeber, G., Ferro, J. M., & Tsai, F. Y. (2011) · Stroke · doi:10.1161/str.0b013e31820a8364 · Cited by 1,970
Self-citationvon Kummer, R., Broderick, J. P., Campbell, B. C. V., Demchuk, A., Goyal, M., Hill, M. D., Treurniet, K. M., Majoie, C. B. L. M., Marquering, H. A., Mazya, M. V., et al. (2015) · Stroke · doi:10.1161/strokeaha.115.010049 · Cited by 1,409
Ferro, J. M., Bousser, M. ‐., Canhão, P., Coutinho, J. M., Crassard, I., Dentali, F., di Minno, M., Maino, A., Martinelli, I., Masuhr, F., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13381 · Cited by 749
Self-citationEFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients
Einhäupl, K., Stam, J., Bousser, M. ‐., De Bruijn, S. F. T. M., Ferro, J. M., Martinelli, I., & Masuhr, F. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03011.x · Cited by 528
Self-citationThe Incidence of Cerebral Venous Thrombosis: A Cross-Sectional Study
Coutinho, J. M., Zuurbier, S. M., Aramideh, M., & Stam, J. (2012) · Stroke · doi:10.1161/strokeaha.112.671453 · Cited by 469
Self-citationDevasagayam, S., Wyatt, B., Leyden, J., & Kleinig, T. (2016) · Stroke · doi:10.1161/strokeaha.116.013617 · Cited by 327
Long-Term Evaluation of the Risk of Recurrence After Cerebral Sinus-Venous Thrombosis
Martinelli, I., Bucciarelli, P., Passamonti, S. M., Battaglioli, T., Previtali, E., & Mannucci, P. M. (2010) · Circulation · doi:10.1161/circulationaha.109.927046 · Cited by 154
Ntaios, G., Papavasileiou, V., Diener, H.-C., Makaritsis, K. P., & Michel, P. (2017) · International Journal of Stroke · doi:10.1177/1747493017700663 · Cited by 129
Self-citationVenous Thromboembolic Events After Cerebral Vein Thrombosis
Miranda, B., Ferro, J. M., Canhão, P., Stam, J., Bousser, M., Barinagarrementería, F., Scoditti, U., & the ISCVT Investigators (2010) · Stroke · doi:10.1161/strokeaha.110.581223 · Cited by 118
Self-citationNovel Factor Xa Inhibitor for the Treatment of Cerebral Venous and Sinus Thrombosis
Geisbüsch, C., Richter, D., Herweh, C., Ringleb, P. A., & Nagel, S. (2014) · Stroke · doi:10.1161/strokeaha.114.006167 · Cited by 103
Self-citationJanghorbani, M., Zare, M., Saadatnia, M., Mousavi, S., Mojarrad, M., & Asgari, E. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00915.x · Cited by 100
Mendonça, M., Barbosa, R. P., Silva, V. C. E., Calado, S., & Baptista, M. V. (2015) · International Journal of Stroke · doi:10.1111/ijs.12462 · Cited by 80
Beyer‐Westendorf, J., & Buller, H. R. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04507.x · Cited by 59
Apixaban for the treatment of cerebral venous thrombosis: A case series
Rao, S. K., Ibrahim, M., Hanni, C. M., Suchdev, K., Parker, D. L., Rajamani, K., & Mohamed, W. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.09.007 · Cited by 43
Buller, H. R., Halperin, J. L., Bounameaux, H., & Prins, M. H. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02848.x · Cited by 40
State of play and future direction with NOACs: An expert consensus
Cohen, A. T., Lip, G. Y. H., Caterina, R. D., Heidbüchel, H., Zamorano, J. L., Agnelli, G., Verheugt, F. W. A., & Camm, A. J. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.04.001 · Cited by 11
Cited by
Saposnik, G., Bushnell, C., Coutinho, J. M., Field, T. S., Furie, K. L., Galadanci, N., Kam, W., Kirkham, F. C., McNair, N. D., Singhal, A. B., et al. (2024) · Stroke · doi:10.1161/str.0000000000000456 · Cited by 306
Self-citation
Metadata
- Authors
- Ferro, J. M., Coutinho, J. M., Dentali, F., Kobayashi, A., Alasheev, A., Canhão, P., Karpov, D., Nagel, S., Posthuma, L., Roriz, J. M., Caria, J., Frässdorf, M., Huisman, H., Reilly, P., Diener, H.-C., & for the RE-SPECT CVT Study Group
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-12-01
- Volume
- 76
- Issue
- 12
- Pages
- 1457
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2971583509
- Cited by
- 311
- References
- 21
- FWCI
- 20.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.